These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38498903)

  • 41. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
    Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
    Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
    Isham CR; Bossou AR; Negron V; Fisher KE; Kumar R; Marlow L; Lingle WL; Smallridge RC; Sherman EJ; Suman VJ; Copland JA; Bible KC
    Sci Transl Med; 2013 Jan; 5(166):166ra3. PubMed ID: 23283368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P; Su Z; Zhang Z; Gao T
    Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
    Che HY; Guo HY; Si XW; You QY; Lou WY
    Tumour Biol; 2014 Sep; 35(9):8659-64. PubMed ID: 24867098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphorylation of H2A by Bub1 prevents chromosomal instability through localizing shugoshin.
    Kawashima SA; Yamagishi Y; Honda T; Ishiguro K; Watanabe Y
    Science; 2010 Jan; 327(5962):172-7. PubMed ID: 19965387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
    Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
    Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
    Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
    Zhu W; Xie B
    Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.
    Liao Y; Hua Y; Li Y; Zhang C; Yu W; Guo P; Zou K; Li W; Sun Y; Wang R; Zuo Y; Sui S; Tian C; Hao J; Chen M; Hu S; Chen M; Long Q; Wang X; Zou L; Xie F; Guo W; Deng W
    Cell Death Differ; 2021 Apr; 28(4):1347-1363. PubMed ID: 33162555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Knockdown of BUB1 inhibits tumor necrosis factor-α-induced proliferation and migration of rheumatoid arthritis synovial fibroblasts by regulating PI3K/Akt pathway.
    He Q; Jia L; Wang X; Feng D; Mao T
    Int J Rheum Dis; 2023 Oct; 26(10):2024-2030. PubMed ID: 37593912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20.
    Morrow CJ; Tighe A; Johnson VL; Scott MI; Ditchfield C; Taylor SS
    J Cell Sci; 2005 Aug; 118(Pt 16):3639-52. PubMed ID: 16046481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
    Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
    Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bub1 kinase activity drives error correction and mitotic checkpoint control but not tumor suppression.
    Ricke RM; Jeganathan KB; Malureanu L; Harrison AM; van Deursen JM
    J Cell Biol; 2012 Dec; 199(6):931-49. PubMed ID: 23209306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524.
    Baron AP; von Schubert C; Cubizolles F; Siemeister G; Hitchcock M; Mengel A; Schröder J; Fernández-Montalván A; von Nussbaum F; Mumberg D; Nigg EA
    Elife; 2016 Feb; 5():. PubMed ID: 26885717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-199a-5p suppresses epithelial- mesenchymal-transition in anaplastic thyroid carcinoma cells via targeting Snail signals.
    Hao F; Bi YN; Wang L; Wang Y; Ma J; Cui P; Li X; Sun S; Ning L; Huang Y; Jiao X; Chen D
    Cancer Biomark; 2020; 29(3):317-326. PubMed ID: 32716347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways.
    Huang Z; Wang S; Wei H; Chen H; Shen R; Lin R; Wang X; Lan W; Lin R; Lin J
    J Cell Mol Med; 2021 Sep; 25(17):8442-8453. PubMed ID: 34337852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation.
    Yu HG; Bijian K; da Silva SD; Su J; Morand G; Spatz A; Alaoui-Jamali MA
    Oncogene; 2022 May; 41(21):2984-2999. PubMed ID: 35449243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
    Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
    Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
    Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
    Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.